Dr. Ruben Mesa on Impact of New NCCN Guidelines for MPN

Ruben Mesa, MD
Published: Friday, Oct 07, 2016


Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the significance of the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN).  
 
Prior to these guidelines management for MPN has been largely based on medical school teachings, review courses, and review articles, and European guidelines, says Mesa.
 
The NCCN guidelines are the first evidence-based, highly rigorous, U.S.-based guidelines. It will be very helpful in terms of clarifying a standard of care for insurance providers and CMS, but also in terms of improving quality and uniformity around treatment of myelofibrosis.
SELECTED
LANGUAGE

Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the significance of the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN).  
 
Prior to these guidelines management for MPN has been largely based on medical school teachings, review courses, and review articles, and European guidelines, says Mesa.
 
The NCCN guidelines are the first evidence-based, highly rigorous, U.S.-based guidelines. It will be very helpful in terms of clarifying a standard of care for insurance providers and CMS, but also in terms of improving quality and uniformity around treatment of myelofibrosis.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x